(NASDAQ: ADIL) Adial Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.78%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.53%.
Adial Pharmaceuticals's earnings in 2026 is -$8,051,798.On average, 4 Wall Street analysts forecast ADIL's earnings for 2026 to be -$9,419,925, with the lowest ADIL earnings forecast at -$11,988,996, and the highest ADIL earnings forecast at -$6,548,611. On average, 4 Wall Street analysts forecast ADIL's earnings for 2027 to be -$8,808,242, with the lowest ADIL earnings forecast at -$12,224,074, and the highest ADIL earnings forecast at -$5,037,393.
In 2028, ADIL is forecast to generate -$13,946,383 in earnings, with the lowest earnings forecast at -$13,399,466 and the highest earnings forecast at -$14,356,571.